Pancreatic Cancer Research

ResearcherUniversity of VirginiaActive in the last 2 years

Matthew J Lazzara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4244-6599; OpenAlex author ID A5089369638; NIH RePORTER profile ID 8200505. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
1
Labs led
1
Collaborators
11
Papers, trials and grants by year

2023: 1 grant · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 2

  1. Plectin promotes an aggressive phenotype and represses cytotoxic T cell activity in pancreatic cancer. Co-author DOI 10.3389/fimmu.2026.1894080↗
  2. A Histone Methylation-MAPK Signaling Axis Drives Durable Epithelial-Mesenchymal Transition in Hypoxic Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-22-2945↗

Grants 1

  1. Optimal control models of epithelial-mesenchymal transition for the design of pancreas cancer combination therapy U01CA243007↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lisa M. Coussens · 1 shared paper, 2026 · strength 0.29
  2. Cody L. Wolf · 1 shared paper, 2026 · strength 0.29
  3. Kimberly A. Kelly · 1 shared paper, 2026 · strength 0.29
  4. Kyoung Eun Lee · 1 shared paper, 2024 · strength 0.17
  5. Michelle C Barbeau · 1 shared paper, 2024 · strength 0.17
  6. Brooke A. Brown · 1 shared paper, 2024 · strength 0.17
  7. William J. Kane · 1 shared paper, 2024 · strength 0.17
  8. Ben Z. Stanger · 1 shared paper, 2024 · strength 0.17
  9. Todd W. Bauer · 1 shared paper, 2024 · strength 0.17
  10. Jason Robert Pitarresi · 1 shared paper, 2024 · strength 0.17
  11. M. Celeste Simon · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.